These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 17404091

  • 1. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors.
    Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ.
    Clin Cancer Res; 2007 Apr 01; 13(7):2091-9. PubMed ID: 17404091
    [Abstract] [Full Text] [Related]

  • 2. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG.
    Clin Cancer Res; 2002 Jul 01; 8(7):2157-66. PubMed ID: 12114416
    [Abstract] [Full Text] [Related]

  • 3. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6512-21. PubMed ID: 15475438
    [Abstract] [Full Text] [Related]

  • 4. A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
    Salazar R, Bissett D, Twelves C, Breimer L, DeMario M, Campbell S, Zhi J, Ritland S, Cassidy J.
    Clin Cancer Res; 2004 Jul 01; 10(13):4374-82. PubMed ID: 15240525
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):173-82. PubMed ID: 16308697
    [Abstract] [Full Text] [Related]

  • 6. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
    Moulder SL, Mahany JJ, Lush R, Rocha-Lima C, Langevin M, Ferrante KJ, Bartkowski LM, Kajiji SM, Noe DA, Paillet S, Sullivan DM.
    Clin Cancer Res; 2004 Nov 01; 10(21):7127-35. PubMed ID: 15534083
    [Abstract] [Full Text] [Related]

  • 7. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
    Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ.
    Clin Cancer Res; 2005 Aug 01; 11(15):5472-80. PubMed ID: 16061863
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.
    Tabernero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH.
    Clin Cancer Res; 2011 Oct 01; 17(19):6313-21. PubMed ID: 21831953
    [Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J.
    Clin Cancer Res; 2001 Jul 01; 7(7):1912-22. PubMed ID: 11448904
    [Abstract] [Full Text] [Related]

  • 12. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 13. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS.
    J Clin Oncol; 2007 Jun 10; 25(17):2369-76. PubMed ID: 17557949
    [Abstract] [Full Text] [Related]

  • 14. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA.
    Clin Cancer Res; 2009 Apr 01; 15(7):2552-8. PubMed ID: 19318484
    [Abstract] [Full Text] [Related]

  • 15. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.
    Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J.
    Cancer Chemother Pharmacol; 2005 Feb 01; 55(2):136-42. PubMed ID: 15592721
    [Abstract] [Full Text] [Related]

  • 16. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS.
    J Clin Oncol; 2006 Sep 01; 24(25):4092-9. PubMed ID: 16943527
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
    Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG.
    J Clin Oncol; 2000 Jan 01; 18(1):178-86. PubMed ID: 10623708
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
    Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G.
    J Clin Oncol; 2005 Aug 20; 23(24):5474-83. PubMed ID: 16027439
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW.
    J Clin Oncol; 2008 Jan 20; 26(3):361-7. PubMed ID: 18202410
    [Abstract] [Full Text] [Related]

  • 20. Phase I study of everolimus in pediatric patients with refractory solid tumors.
    Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL.
    J Clin Oncol; 2007 Oct 20; 25(30):4806-12. PubMed ID: 17947729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.